Hiroshi Inaba¹, Keiko Shinozawa², Kagehiro Amano^1,2, Katsuyuki Fukutake^1,2, Ei Kinai¹ (1.Dept. of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan, 2.Dept. of Molecular Genetics of Coagulation Disorders, Tokyo Medical University)

Koji Yada^1,2, Natsume Tsubota³, Keiji Nogami¹, Midori Shima^1,2 (1.Department of Pediatrics, Nara Medical University, 2.The course of hemophilia education, Nara Medical University, 3.Nara Medical University)

Azusa Nagao¹, Yuji Sato², Sayaka Nagami³, Haruna Katayama¹, Takashi Suzuki¹ (1.Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan, 2.Department of Neurosurgery, Nadogaya-Abiko Hospital, Chiba, Japan, 3.Chugai Pharmaceutical Co., Ltd, Tokyo, Japan)

Naoya Yamasaki, Teruhisa Fujii (Division of Blood Transfusion., Hiroshima University Hospital., Hiroshima, Japan)

Keita Tomioka, Shiho Nishimura, Yoshiko Matsubara, Naoya Yamasaki, Hiroshi Kawaguchi, Teruhisa Fujii, Masao Kobayashi (Hemophilia Treatment Center, Hiroshima University Hospital, Hiroshima, Japan)

Azusa Nagao¹, Hideyuki Takedani², Shougo Sugimoto¹, Kayo Maekawa¹, Ikuko Wada¹, Haruna Katayama¹, Takashi Suzuki¹ (1.Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan, 2.Department of Joint Surgery, IMSUT Hospital, Tokyo University, Tokyo, Japan)